Streptococcal toxic shock syndrome due to <i>Streptococcus dysgalactiae</i> subsp. <i>equisimilis from</i> retroperitoneal panniculitis during the treatment with anti-IL-6 receptor antibody: A case report-Reference-Cited by-同舟云学术

Streptococcal toxic shock syndrome due to Streptococcus dysgalactiae subsp. equisimilis from retroperitoneal panniculitis during the treatment with anti-IL-6 receptor antibody: A case report

Published:2024-01-12 Issue:2 Volume:8 Page:255-258
ISSN:2472-5625
Container-title:Modern Rheumatology Case Reports
language:en
Short-container-title:

Author:

Fujimoto Sho¹^ORCID,Eriguchi Yoshihiro¹^ORCID,Nakamura Rinto¹,Kamikawa Sota¹,Yonekawa Akiko¹,Miyake Noriko¹,Ono Nobuyuki¹,Niiro Hiroaki²^ORCID

Affiliation:

1. Department of Clinical Immunology and Rheumatology/Infectious Disease, Kyushu University Hospital , Fukuoka, Japan

2. Department of Medical Education, Faculty of Medical Sciences, Kyushu University Graduate School of Medical Sciences , Fukuoka, Japan

Abstract

ABSTRACT A 53-year-old man with adult-onset Still’s disease developed severe streptococcal toxic shock syndrome (STSS) due to Streptococcus dysgalactiae subsp. equisimilis (SDSE), following retroperitoneal panniculitis. He was receiving tocilizumab (TCZ), an interleukin-6 receptor inhibitor. The modifying effect of TCZ on the immune response and the pathophysiology of SDSE infection may have led to retroperitoneal panniculitis and atypical STSS with delayed shock and flare of soft tissue inflammation.

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/mrcr/advance-article-pdf/doi/10.1093/mrcr/rxae001/56532299/rxae001.pdf

Reference27 articles.

1. Streptococcal toxic shock syndrome;Stevens;Clin Microbiol Infect,2002

2. Increased prevalence of group A streptococcus isolates in streptococcal toxic shock syndrome cases in Japan from 2010 to 2012;Ikebe;Epidemiol Infect,2015

3. Risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments;Xie;Arthritis Rheumatol,2016

4. Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept;Rempenault;Rheumatology,2022

5. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs;Strangfeld;Ann Rheum Dis,2017

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tocilizumab;Reactions Weekly;2024-08-03